# Filing Detail

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0000912282-11-000145
Filing Date
2011-03-24
Accepted
2011-03-24 17:17:05
Documents
14
Period of Report
2010-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | oncolytics_20f-12312010.htm | 20-F | 2144436
2 | AMENDMENT NO. 2, DATED JANUARY 1, 2011, TO THE EXECUTIVE EMPLOYMENT AGREEMENT BE | ex4_17.htm | EX-4.17 | 2357
3 | LIST OF SUBSIDIARIES | ex8_1.htm | EX-8.1 | 3779
4 | CERTIFICATION OF CHIEF EXECUTIVE OFFICER | ex12_1.htm | EX-12.1 | 13221
5 | CERTIFICATION OF CHIEF FINANCIAL OFFICER | ex12_2.htm | EX-12.2 | 12715
6 | CERTIFICATION OF CHIEF EXECUTIVE OFFICER | ex13_1.htm | EX-13.1 | 7254
7 | CERTIFICATION OF CHIEF FINANCIAL OFFICER | ex13_2.htm | EX-13.2 | 6133
8 | THE REGISTRANT'S MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED DECEMBE | ex15_1.htm | EX-15.1 | 488334
9 | CONSENT OF ERNST & YOUNG LLP | ex15_2.htm | EX-15.2 | 6546
10 |  | oncolytics_logo.jpg | GRAPHIC | 12620
11 |  | reovirus.jpg | GRAPHIC | 86821
12 |  | ernstyounglogo.jpg | GRAPHIC | 6545
13 |  | onco_p1.jpg | GRAPHIC | 250282
14 |  | onco_p2.jpg | GRAPHIC | 263488
| Complete submission text file | 0000912282-11-000145.txt |  | 3540298

Mailing Address 210 - 1167 KENSINGTON CRES NW CALGARY A0 T2N 1X7
Business Address 1167 KENSINGTON CRES NW SUITE 210 CALGARY ALBERTA CANADA T2N 1X7 ALBERTA CANADA A0 00000 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 000-31062 | Film No.: 11710205
SIC: 2834 Pharmaceutical Preparations